The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

Blood

Volumn 114, Issue 20, 2009, Pages 4369-4372

  Paiva, Bruno ^a   Vidriales, Maria Belén ^a,b   Mateo, Gema ^a,b   Pérez, Jose J ^a   Montalbán, Maria Angeles ^c   Sureda, Anna ^d   Montejano, Laura ^c   Gutiérrez, Norma C ^a,b   De Coca, Alfonso García ^e   De Las Heras, Natalia ^f   Mateos, Maria Victoria ^a,b   López Berges, Maria Consuelo ^a   García Boyero, Raimundo ^g   Galende, Josefina ^h   Hernández, Jose ⁱ   Palomera, Luis ^j   Carrera, Dolores ^k   Martínez, Rafael ^l   De La Rubia, Javier ^m   Martín, Alejandro ⁿ   González, Yolanda ^o   Bladé, Joan ^p   Lahuerta, Juan José ^c   Orfao, Alberto ^b,q   San Miguel, Jesús F ^a,b   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f HOSPITAL DE LEÓN   (Spain)

^g HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^h HOSPITAL EL BIERZO   (Spain)

ⁱ HOSPITAL GENERAL DE SEGOVIA   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^m HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁿ HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^o HOSPITAL JOSEP TRUETA   (Spain)

^p HOSPITAL CLÍNIC   (Spain)

^q UNIVERSITY OF SALAMANCA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY;

ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS;

EID: 73349127140     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-221689     Document Type: Article

References (21)

1. Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26(16):2737-2744.
2. Mateo MG, San M, I, Orfao de MA. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med. 2005;113:5-24.
3. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152(6):1655-1665.
4. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586-2592.
5. Liu H, Yuan C, Heinerich J, et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma. 2008;49(2):306-314.
6. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
7. Rawstron AC, Davies FE, Dasgupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100(9):3095- 4100.
8. San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99(5):1853-1856.
9. Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol. 2008;8:13.
10. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
11. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
12. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365-1372.
13. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558.
14. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438.
15. Sezer O, Heider U, Zavrski I, Possinger K. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica. 2001;86(8):837-843.
16. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates. Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91(7):2501-2507.
17. San Miguel JF, Sanchez J, Gonzalez M. Prognostic factors and classification in multiple myeloma. Br J Cancer. 1989;59(1):113-118.
18. Greipp PR, San MJ, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
19. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276-2279.
20. Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005;11(10):3661-3667.
21. Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells: identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica. 2006;91(9):1234-1240.